Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

BACKGROUND: Targeting the MDM2-p53 interaction using AMG 232 is synergistic with MAPK inhibitors (MAPKi) in preclinical melanoma models. We postulated that AMG 232 plus MAPKi is safe and more effective than MAPKi alone in TP53-wild type, MAPKi-naïve metastatic melanoma. METHODS: Patients were treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Moschos, Stergios J., Sandhu, Shahneen, Lewis, Karl D., Sullivan, Ryan J., Puzanov, Igor, Johnson, Douglas B., Henary, Haby A., Wong, Hansen, Upreti, Vijay V., Long, Georgina V., Flaherty, Keith T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395504/
https://www.ncbi.nlm.nih.gov/pubmed/35635631
http://dx.doi.org/10.1007/s10637-022-01253-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395504/
https://www.ncbi.nlm.nih.gov/pubmed/35635631
http://dx.doi.org/10.1007/s10637-022-01253-3

Ejemplares similares